UnitedHealth Forecast, price target & analysts
UnitedHealth Target price 2025 - Analyst rating & recommendation
UnitedHealth Classifications & Recommendation:
UnitedHealth Price Target
| Target Price | $405.45 |
| Price | $332.52 |
| Potential | 21.93% |
| Number of Estimates | 28 |
| 28 Analysts have issued a price target UnitedHealth 2026 . The average UnitedHealth target price is $405.45. This is 21.93% higher than the current stock price. The highest price target is $462.00 38.94% , the lowest is $199.98 39.86% . | |
| A rating was issued by 34 analysts: 23 Analysts recommend UnitedHealth to buy, 8 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the UnitedHealth stock has an average upside potential 2026 of 21.93% . Most analysts recommend the UnitedHealth stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
30 Analysts have issued a sales forecast UnitedHealth 2025 . The average UnitedHealth sales estimate is $452b . This is 3.87% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $472b 8.50% , the lowest is $435b 0.12% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $400b | 7.71% |
|---|---|---|
| 2025 | $452b | 12.92% |
| 2026 | $460b | 1.87% |
| 2027 | $483b | 4.80% |
| 2028 | $508b | 5.23% |
| 2029 | $545b | 7.37% |
| 2030 | $588b | 7.77% |
| 2031 | $620b | 5.54% |
| 2032 | $654b | 5.52% |
23 Analysts have issued an UnitedHealth EBITDA forecast 2025. The average UnitedHealth EBITDA estimate is $27.3b . This is 10.87% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $39.5b 28.84% , the lowest is $25.2b 17.83% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $36.4b | 0.15% |
|---|---|---|
| 2025 | $27.3b | 24.94% |
| 2026 | $29.4b | 7.58% |
| 2027 | $32.7b | 11.20% |
| 2028 | $38.0b | 16.30% |
| 2029 | $44.6b | 17.34% |
| 2030 | $54.3b | 21.79% |
| 2031 | $59.3b | 9.20% |
| 2032 | $62.9b | 5.99% |
EBITDA Margin
| 2024 | 9.09% | 7.02% |
|---|---|---|
| 2025 | 6.04% | 33.55% |
| 2026 | 6.38% | 5.63% |
| 2027 | 6.77% | 6.11% |
| 2028 | 7.48% | 10.49% |
| 2029 | 8.18% | 9.36% |
| 2030 | 9.24% | 12.96% |
| 2031 | 9.56% | 3.46% |
| 2032 | 9.60% | 0.42% |
32 UnitedHealth Analysts have issued a net profit forecast 2025. The average UnitedHealth net profit estimate is $14.9b . This is 15.33% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $15.7b 10.76% , the lowest is $14.2b 19.23% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $14.4b | 35.64% |
|---|---|---|
| 2025 | $14.9b | 3.39% |
| 2026 | $16.1b | 8.41% |
| 2027 | $19.0b | 17.58% |
| 2028 | $24.0b | 26.23% |
| 2029 | $29.2b | 21.87% |
| 2030 | $39.2b | 34.28% |
| 2031 | $45.5b | 15.98% |
| 2032 | $50.8b | 11.75% |
Net Margin
| 2024 | 3.60% | 40.25% |
|---|---|---|
| 2025 | 3.29% | 8.58% |
| 2026 | 3.51% | 6.69% |
| 2027 | 3.93% | 11.97% |
| 2028 | 4.72% | 20.10% |
| 2029 | 5.36% | 13.56% |
| 2030 | 6.67% | 24.44% |
| 2031 | 7.33% | 9.90% |
| 2032 | 7.77% | 6.00% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
32 Analysts have issued a UnitedHealth forecast for earnings per share. The average UnitedHealth EPS is $16.44 . This is 15.13% lower than earnings per share in the financial year 2024. The highest EPS forecast is $17.33 10.53% , the lowest is $15.68 19.05% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $15.51 | 35.00% |
|---|---|---|
| 2025 | $16.44 | 6.00% |
| 2026 | $17.82 | 8.39% |
| 2027 | $20.96 | 17.62% |
| 2028 | $26.45 | 26.19% |
| 2029 | $32.24 | 21.89% |
| 2030 | $43.29 | 34.27% |
| 2031 | $50.21 | 15.99% |
| 2032 | $56.11 | 11.75% |
P/E ratio
| Current | 17.17 | 57.10% |
|---|---|---|
| 2025 | 20.23 | 17.84% |
| 2026 | 18.66 | 7.76% |
| 2027 | 15.87 | 14.95% |
| 2028 | 12.57 | 20.79% |
| 2029 | 10.31 | 17.98% |
| 2030 | 7.68 | 25.51% |
| 2031 | 6.62 | 13.80% |
| 2032 | 5.93 | 10.42% |
Based on analysts' sales estimates for 2025, the UnitedHealth stock is valued at an EV/Sales of 0.78 and an P/S ratio of 0.67 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 0.81 | 50.61% |
|---|---|---|
| 2025 | 0.78 | 3.27% |
| 2026 | 0.77 | 1.84% |
| 2027 | 0.73 | 4.59% |
| 2028 | 0.70 | 4.96% |
| 2029 | 0.65 | 6.87% |
| 2030 | 0.60 | 7.22% |
| 2031 | 0.57 | 5.24% |
| 2032 | 0.54 | 5.24% |
P/S ratio
| Current | 0.69 | 51.89% |
|---|---|---|
| 2025 | 0.67 | 3.73% |
| 2026 | 0.65 | 1.85% |
| 2027 | 0.62 | 4.59% |
| 2028 | 0.59 | 4.97% |
| 2029 | 0.55 | 6.86% |
| 2030 | 0.51 | 7.20% |
| 2031 | 0.49 | 5.27% |
| 2032 | 0.46 | 5.23% |
Current UnitedHealth Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Hold
➜
Hold
|
Unchanged | Oct 30 2025 |
| Bernstein |
Outperform
➜
Outperform
|
Unchanged | Oct 30 2025 |
| UBS |
Buy
➜
Buy
|
Unchanged | Oct 29 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 29 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 29 2025 |
| Jefferies |
Buy
➜
Buy
|
Unchanged | Oct 17 2025 |
| Goldman Sachs |
➜
Buy
|
Initiated | Oct 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
TD Cowen:
Hold
➜
Hold
|
Oct 30 2025 |
|
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Oct 30 2025 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Oct 29 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 29 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 29 2025 |
|
Unchanged
Jefferies:
Buy
➜
Buy
|
Oct 17 2025 |
|
Initiated
Goldman Sachs:
➜
Buy
|
Oct 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
